CIFAR fellow on team that wins $75 million to fight heart disease
Roth (University of Toronto Donnelly Centre for Cellular & Biomolecular Research & Lunenfeld-Tanenbaum Research Institute), is co-director of CIFAR’s Genetic Networks program.
The award was given by the American Heart Association, Verily Life Sciences (formerly Google Life Sciences) and AstraZeneca, and supports innovative joint initiatives that seek a cure for coronary heart disease. The award will fund the team’s work to define the earliest genetic and molecular markers of coronary heart disease in order to prevent the disease’s onset.
In addition to Roth, the team includes researchers from Brigham and Women’s Hospital in Boston, MIT, the Stanford University Data Science Initiative, Northeastern University, the Million Veteran Program, and Boston University School of Medicine.
The team will attempt to identify upstream biologic or cellular traits as well as behavioral features with a clear genetic basis that can be used as early and definitive biomarkers of coronary heart disease. They also hope to create a global consortium to establish a lasting resource for future research endeavors in cardiovascular and other chronic disease.
With his expertise in computational biology and genomics, Roth brings a background developing technologies to accelerate the discovery of gene functions, the pathways they encode, and the relationships of genes and pathways and variation to human disease. These new technologies will help researchers study gene function and the inaction of these functions more efficiently.
Senior Fellow Joel Levine can remember the morning of October 2 vividly. It was not yet dawn as he drove...
Exposure to antibiotics disrupts the balance of bacterial communities in the gut microbiome and may spur the onset of type-1...